Highlights
- Market Cap
- $48.34B
- Enterprise Value
- $44.94B
- EPS (TTM)
- $32.69
- PE Ratio
- 22.34
- PEG Ratio
- 0.43
- Total Revenue (TTM)
- $5.49B
- Gross Profit (TTM)
- $4.38B
- EBITDA (TTM)
- $1.50B
- Year Range
- $510.06 - $934.62
- Target Price
- $1,026.71
- ROA (TTM)
- 24.82%
- ROE (TTM)
- 29.43%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in argenx SE, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
argenx SE (ARGX) has returned -13.16% so far this year and 23.38% over the past 12 months.
argenx SE
- 1D
- 3.68%
- 1M
- -4.78%
- YTD
- -13.16%
- 6M
- -0.99%
- 1Y
- 23.38%
- 3Y*
- 25.15%
- 5Y*
- 20.93%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since May 18, 2017, ARGX's average daily return is +0.20%, while the average monthly return is +4.13%. At this rate, your investment would double in approximately 1.4 years.
Historically, 58% of months were positive and 42% were negative. The best month was Dec 2017 with a return of +97.2%, while the worst month was Jan 2022 at -23.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ARGX closed higher 50% of trading days. The best single day was Dec 11, 2017 with a return of +78.9%, while the worst single day was Dec 20, 2023 at -25.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.05% | -8.75% | -4.78% | -13.16% | |||||||||
| 2025 | 6.53% | -4.65% | -5.25% | 9.00% | -11.14% | -3.84% | 21.61% | 6.25% | 3.56% | 10.97% | 11.42% | -7.79% | 36.74% |
| 2024 | 0.02% | -0.13% | 3.61% | -4.63% | -1.19% | 15.91% | 19.96% | 0.28% | 4.79% | 8.16% | 5.16% | -0.25% | 61.66% |
| 2023 | 0.90% | -4.25% | 1.79% | 4.11% | 0.21% | 0.26% | 29.44% | -0.39% | -2.16% | -4.49% | -4.04% | -15.57% | 0.42% |
| 2022 | -23.11% | 6.85% | 9.59% | -8.88% | 7.65% | 22.50% | -3.87% | 3.75% | -6.57% | 9.88% | 2.59% | -4.81% | 8.18% |
| 2021 | -0.36% | 12.85% | -16.72% | 4.11% | -2.69% | 7.91% | 1.12% | 8.73% | -8.77% | -0.01% | -7.53% | 25.42% | 19.08% |
Benchmark Metrics
argenx SE has an annualized alpha of 50.69%, beta of 0.73, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since May 19, 2017.
- This stock captured 200.04% of S&P 500 Index gains but only 60.98% of its losses — a favorable profile for investors.
- R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 50.69%
- Beta
- 0.73
- R²
- 0.07
- Upside Capture
- 200.04%
- Downside Capture
- 60.98%
Return for Risk
Risk / Return Rank
ARGX ranks 61 for risk / return — better than 61% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for argenx SE (ARGX) and compare them to a chosen benchmark (S&P 500 Index).
| ARGX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.71 | 0.90 | -0.19 |
Sortino ratioReturn per unit of downside risk | 1.19 | 1.39 | -0.19 |
Omega ratioGain probability vs. loss probability | 1.16 | 1.21 | -0.06 |
Calmar ratioReturn relative to maximum drawdown | 0.84 | 1.40 | -0.56 |
Martin ratioReturn relative to average drawdown | 2.17 | 6.61 | -4.44 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore ARGX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the argenx SE. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the argenx SE was 38.20%, occurring on Dec 20, 2023. Recovery took 177 trading sessions.
The current argenx SE drawdown is 21.45%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -38.2% | Jul 24, 2023 | 106 | Dec 20, 2023 | 177 | Sep 5, 2024 | 283 |
| -36.29% | Jun 13, 2018 | 84 | Oct 10, 2018 | 19 | Nov 6, 2018 | 103 |
| -34.13% | Jan 10, 2020 | 45 | Mar 16, 2020 | 49 | May 26, 2020 | 94 |
| -33.09% | Feb 12, 2021 | 242 | Jan 27, 2022 | 108 | Jul 5, 2022 | 350 |
| -29.18% | Jul 19, 2019 | 57 | Oct 8, 2019 | 40 | Dec 4, 2019 | 97 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of argenx SE over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how argenx SE is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ARGX, comparing it with other companies in the Biotechnology industry. Currently, ARGX has a P/E ratio of 22.3. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ARGX compared to other companies in the Biotechnology industry. ARGX currently has a PEG ratio of 0.4. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ARGX relative to other companies in the Biotechnology industry. Currently, ARGX has a P/S ratio of 8.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ARGX in comparison with other companies in the Biotechnology industry. Currently, ARGX has a P/B value of 6.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |